News Archives - Integra Connect

Community Oncology Practices Working with Integra Connect Achieve Clinical and Financial Success under The Center for Medicare & Medicaid Innovation’s Oncology Care Model

Integra Connect, LLC., a leader in value-based, precision medicine solutions for specialty care, today announced that its network of community oncology practices drove measurable improvements in cancer care during the most recent performance period of The Center for Medicare & Medicaid Innovation’s (CMMI) Oncology Care Model (OCM).

Integra Connect Statement on the Enhancing Oncology Model

Integra Connect, LLC. is pleased that the Centers for Medicare & Medicaid Services’ (CMS) Center for Medicare & Medicaid Innovation (CMMI) announced the next iteration of its value-based, oncology care…

Integra Connect to Share Study Results Underscoring the Importance of Early and Rapid Genetic Testing for Improved Survival Rates in Patients with Newly Diagnosed, Stage 4 Non-Small Cell Lung Cancer

WEST PALM BEACH, Fla. Integra Connect, the leading provider of value-based, precision medicine solutions and services for specialty care, will present findings from a retrospective observational study in newly diagnosed, stage 4 non-small cell lung cancer (NSCLC) that demonstrates improved patient survival rates when molecular testing is applied prior to initiating treatment. The results will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting on June 4 at 1:15 p.m. CST.

New real-world data show potential of Trilaciclib to reduce the substantial burden of myelosuppression in patients with extensive-stage small-cell lung cancer treated with chemotherapy

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced results of a retrospective, observational study describing the substantial burden of myelosuppression and its impact on healthcare resource utilization (HCRU) in 3,277 patients being treated with chemotherapy for extensive-stage small-cell lung cancer (ES-SCLC). The study also described patient outcomes from 21 patients receiving trilaciclib prior to chemotherapy; of these, 17 received commercial trilaciclib in the real-world setting, and four received trilaciclib in clinical trials.

EVERSANA and Integra Connect Form Strategic Partnership to Advance Next Generation Oncology Commercialization Services

CHICAGO, EVERSANA, the pioneer of next generation commercial services to the global life sciences industry, today announced a strategic partnership with Integra Connect, LLC, designed to support life sciences companies as they develop and commercialize new oncology treatments. EVERSANA and Integra Connect, the leading provider of value-based, precision medicine technologies and services for specialty care, will contribute market-leading expertise, real-world data and technologies to create a comprehensive longitudinal oncology patient database. Once available, life sciences companies will be able to leverage the database to optimize their decision-making across a product’s entire life cycle.

Integra Connect Welcomes New COO

WEST PALM BEACH, Fla. — Integra Connect, the leading provider of technologies and services for value-based specialty care and precision oncology, today announces the addition of Cory Wiegert as its new Chief Operating Officer (COO) to provide strategic leadership as the company expands with its integrated solutions for Precision Oncology, Population Health, Cloud EHR and Revenue Cycle management.

International Data Corp. honors 5 AI companies for patient engagement

International Data Corp. highlighted the importance of integrating artificial intelligence into patient engagement by publishing a report on the top five companies using AI to connect with patients. AI can be used to gather more specific insights about patient health, provide recommendations on next best action and give patients guidance.

Five Companies Applying Artificial Intelligence to Patient Engagement Issues Named IDC Innovators

International Data Corporation (IDC) today published an IDC Innovators report profiling five companies that are applying artificial intelligence (AI) to patient engagement in healthcare. The five companies are: Cogitativo, Integra Connect, Jvion, LifeLink, and Medial EarlySign. Healthcare organizations have been slow to adopt AI as they often lack data management and/or data science skills. However, the use of AI embedded in applications is seeing some success in the market. Because of their expanded data ingestion capability and computational expertise, clients utilizing AI can gain more granular insights into the health of their population, receive recommendations on next best action, and provide guidance to patients during their healthcare journey.

Five Companies Applying Artificial Intelligence to Patient Engagement Issues Named IDC Innovators

International Data Corporation (IDC) today published an IDC Innovators report profiling five companies that are applying artificial intelligence (AI) to patient engagement in healthcare. The five companies are: Cogitativo, Integra Connect, Jvion, LifeLink, and Medial EarlySign. Healthcare organizations have been slow to adopt AI as they often lack data management and/or data science skills. However, the use of AI embedded in applications is seeing some success in the market. Because of their expanded data ingestion capability and computational expertise, clients utilizing AI can gain more granular insights into the health of their population, receive recommendations on next best action, and provide guidance to patients during their healthcare journey.

More Savings Are Possible for Oncology Care Model, ASCO Study Says

A real-world study of patients with breast cancer who received febrile neutropenia prophylaxis with biosimilar pegfilgrastim (Udenyca) or reference pegfilgrastim (Neulasta) has not only demonstrated comparable efficacy between the 2 products but also shown that large-scale comparisons of this nature can be done, according to a study presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology.